Post Profile






MGH team identifies possible mechanism for resistance to antiangiogenesis therapy

(Massachusetts General Hospital) Massachusetts General Hospital investigators have identified a potential mechanism behind the resistance that inevitably develops to cancer treatment with a combination of chemotherapy and antiangiogenic drugs.
read more

share

Related Posts


Potential new therapy could reduce dangerous post-heart-attack inflammation

Academics / General Science : Science Codex

A new study led by investigators at Massachusetts General Hospital (MGH) has identified a mechanism behind the surge in cardiovascular inflammation that takes place after a heart attack. Working with collaborators from the Massachus...

Mass. General team identifies new class of antiangiogenesis drugs

Academics / General Science : Science Codex

Massachusetts General Hospital (MGH) researchers have discovered the first of an entirely new class of antiangiogenesis drugs – agents that interfere with the development of blood vessels. In a report in Proceedings of the National ...

Mass. General study identifies potential treatment target for IDH1-mutant cancers

Academics / General Science : Science Codex

A Massachusetts General Hospital (MGH)-based research team has identified a potential new treatment target for tumors - including a significant percentage of malignant brain tumors - driven by mutations in an important metabolic enz...

Study identifies novel treatment resistance mechanism in BRAF-mutant melanoma

Academics / General Science : Science Codex

A Massachusetts General Hospital (MGH) research team has identified an additional mechanism for resistance to targeted treatment for BRAF-mutant melanoma. Their paper, receiving advance online publication in Nature Medicine, reports...

MGH Cancer Center team identifies potential treatment target for KRAS-mutated colon cancer

Academics / General Science : Science Codex

Researchers from the Massachusetts General Hospital (MGH) Cancer Center have identified a new potential strategy for treating colon tumors driven by mutations in the KRAS gene, which usually resist both conventional and targeted tre...

Comments


Copyright © 2016 Regator, LLC